Trial Profile

A first-in-man clinical trial of MZE-782 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MZE 782 (Primary)
Indications Renal failure
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

09 Oct 2024 New trial record
01 Oct 2024 According to a Maze Therapeutics media release, the first participants have been dosed in this trial. The initial results of this clinical trial, including potential proof of mechanism utilizing these biomarkers, are expected to be provided in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com